Patient Perceptions of Integrating Meditation-based Interventions in Office-based Opioid Treatment with Buprenorphine: A Mixed-methods Survey.

J Addict Med

From the Department of Population Health, New York University School of Medicine, New York, NY (BT, CM, JDL); Division of General Internal Medicine, Bellevue Hospital Center, New York, NY (BT, JDL); Center for Drug Use and HIV Research, New York, NY (BT, JDL); Nathan Kline Institute for Psychiatric Research, Orangeburg, NY (BT); Center on Mindfulness and Integrative Health Intervention Development, College of Social Work, University of Utah, Salt Lake City, Utah (ELG).

Published: November 2023

Introduction: Recent findings support the provision of meditation-based interventions (MBIs) in primary care. However, the acceptability of MBI among patients prescribed medications for opioid use disorder (eg, buprenorphine) in primary care remains unclear. This study assessed experiences and preferences for adopting MBI among patients prescribed buprenorphine in office-based opioid treatment (OBOT).

Methods: This 23-item, semistructured cross-sectional survey was administered by study staff to patients enrolled in OBOT (N = 72) and consisted of demographic and clinical characteristics, perceptions, experiences with MBI, and preferred strategies to access MBI to support their treatment on buprenorphine.

Results: Most participants reported practicing at least 1 category of MBI (90.3%) on at least a daily (39.6%) or weekly (41.7%) basis including (1) spiritual meditation (eg, centering prayer; 67.7%); (2) nonmantra meditation (eg, comfortable posture; 61.3%); (3) mindfulness meditation (eg, mindfulness-based stress reduction; 54.8%); and (4) mantra meditation (eg, transcendental meditation; 29.0%). Interest in MBI was motivated by improving one's general health and well-being (73.4%), treatment outcomes with medications for OUD (eg, buprenorphine; 60.9%), and relationships with others (60.9%). Perceived clinical benefits of MBI included reduced anxiety or depression symptoms (70.3%), pain (62.5%), illicit substance or alcohol use (60.9%), cravings for illicit substances (57.8%), and opioid-related withdrawal symptoms (51.6%).

Conclusions: Findings from this study indicate high acceptability for adopting MBI among patients prescribed buprenorphine in OBOT. Further research is needed to assess the efficacy of MBI to improve clinical outcomes among patients initiating buprenorphine in OBOT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10533745PMC
http://dx.doi.org/10.1097/ADM.0000000000001160DOI Listing

Publication Analysis

Top Keywords

mbi patients
12
patients prescribed
12
mbi
9
meditation-based interventions
8
office-based opioid
8
opioid treatment
8
primary care
8
adopting mbi
8
prescribed buprenorphine
8
buprenorphine obot
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!